Schlieren (Zurich), Switzerland, June 19, 2018 - Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15thannual State of Spine Surgery Think [...]
- Subcutaneous formulation offers potential for increased patient convenience and acceptance -
Breda, the Netherlands/Ghent, Belgium, June 14, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage bi [...]
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
The results of the first of two completed Phase 3 trials confirm dasigluca [...]
- IND Accepted in April by the U.S. FDA for MCLA-158 -
UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispeci [...]
Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has enrolled the first patien [...]
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced t [...]
Breda, the Netherlands / Ghent, Belgium, May 9, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatm [...]
Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 -
Strategic collaboration announced with Simcere Pharm [...]
First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor
Multiple sites have already been initiated in the U [...]
Schlieren (Zurich), Switzerland, June 19, 2018 - Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15thannual State of Spine Surgery Think [...]
- Subcutaneous formulation offers potential for increased patient convenience and acceptance -
Breda, the Netherlands/Ghent, Belgium, June 14, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage bi [...]
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
The results of the first of two completed Phase 3 trials confirm dasigluca [...]
- IND Accepted in April by the U.S. FDA for MCLA-158 -
UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispeci [...]
Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has enrolled the first patien [...]
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced t [...]
Breda, the Netherlands / Ghent, Belgium, May 9, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatm [...]
Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 -
Strategic collaboration announced with Simcere Pharm [...]
First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor
Multiple sites have already been initiated in the U [...]
Follow us
